Inhibition of fumarate reductase in Leishmania major and l. donovani by chalcones

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 7, 2001, Pages 2023-2029

  Chen, M ^a   Zhai, L ^a   Christensen, S B ^a   Theander, T G ^a   Kharazmi, A ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHOXY 4' ALLYLOXYCHALCONE; 2,4 DIMETHOXY 4' BUTOXYCHALCONE; ANTILEISHMANIAL AGENT; CHALCONE DERIVATIVE; FUMARATE REDUCTASE; FUMARATE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG MECHANISM; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY CHAIN;

ANIMALS; ANTIPROTOZOAL AGENTS; CHALCONE; CHALCONES; ELECTRON TRANSPORT; ENZYME INHIBITORS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MITOCHONDRIA; NADH DEHYDROGENASE; PERMEABILITY; PHENYLACETATES; SUCCINATE CYTOCHROME C OXIDOREDUCTASE; SUCCINATE DEHYDROGENASE;

EID: 0034951496     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.7.2023-2029.2001     Document Type: Article

References (40)

1. Human leishmaniasis; clinical, diagnostic, and chemotherapeutic developments in the last 10 years
2. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis
3. Intermediary metabolism of Leishmania
4. Energy metabolism in Leishmania
5. Fumarate reductase and other mitochondrial activities in Trypanosoma cruzi
6. Herbicides to curb human parasitic infections; in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans
7. Licochalcone A, a novel antiparasitic agent with potent activity against human-pathogenic protozoan species of Leishmania
8. Licochalcone A, a new antimalarial agengt, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection
9. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani
10. The novel oxygenated chalcone, 2,4-dimethoxy-4′-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo
11. Separation of NADH-fumarate reductase and succinate dehydrogenase activities in Trypanosoma cruzi
12. Succinate-dependent metabolism in Trypanosoma cruzi epimastigotes
13. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages
14. Mitochondria of mammalian Plasmodium spp.
15. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1′-substituted 9-anilinoacridines
16. Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach
17. ESR studies on iron-sulfur clusters of complex II in Ascaris suum mitochondria which exhibits strong fumarate reductase activity
18. Structure of the Escherichia coli fumarate reductase respiratory complex
19. Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design
20. Enzymes of parasite thiol metabolism as drug targets
21. Activity and mode of action of acridine compounds against Leishmania donovani
22. Luteolin, an abundant dietary component, is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis
23. Leishmaniasis
24. A soluble fumarate reductase in Trypanosoma brucei procyclic trypomastigotes
25. Molecular target of the antileishmanial action of sinefugin
26. Practical progress and new drugs for changing patterns of leishmaniasis
27. The Trypanosomatidae: Amazing organisms
28. Practical progress and new drugs for changing patterns of leishmaniasis
29. The fumarate reductase reaction of Haemonchus contortus and the mode of action of some anthelmintics
30. Chemotherapeutic agents. XI. Synthesis of pyrimidines and azolopyrimidines as leishmanicides
31. Characterization of the respiratory chain of Leishmania donovani promastigotes
32. Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target
33. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis
34. Possible role of the NADH-fumarate reductase in superoxide anion and hydrogen peroxide production in Trypanosoma brucei
35. The role of succinate in the respiratory chain of Trypanosoma brucei procyclic trypomastigotes
36. Special programme for research and training in tropical diseases (TDR). Antimonials: Large-scale failure in leishmaniasis "alarming"
37. Leishmaniasis
38. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis
39. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action
40. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria